Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Studies from this laboratory have shown that obese men have elevated serum estrogen levels and diminished levels of follicle-stimulating hormone (FSH) and free and total testosterone, all in proportion to their degree of obesity. The decreases in testosterone and FSH constitute a state of hypogonadotropic hypogonadism (HHG), and we have hypothesized that it results from feedback suppression of the pituitary by the elevated estrogen levels. We tested this hypothesis by lowering the serum estrogens of 6 health obese men (body mass index [BMI], 38 to 73) by administering the aromatase inhibitor testolactone (1 g daily for 6 weeks). Twenty-four-hour mean serum testosterone rose in every subject, from a mean of 290 +/- 165 ng/dL to a mean of 403 +/- 170 (P <.0003); 24-hour mean serum estradiol decreased in every subject, from a mean of 40 +/- 10.8 pg/mL to a mean of 29 +/- 6.7 (P <.004); and 24-hour mean serum luteinizing hormone (LH) increased in every subject, from a mean of 14.3 +/- 4.1 mIU/mL to a mean of 19.3 +/- 5.1 (P <.004). The rise in mean LH was due to an increase in the amplitude of the individual secretory pulses, especially at night. Twenty-four-hour mean serum estrone decreased nonsignificantly, from 48 +/- 14 pg/mL to 39 +/- 6.4, and 24-hour mean serum FSH increased nonsignificantly, from 13.5 +/- 5.3 mIU/mL to 15.0 +/- 5.4. The results are in accordance with the hypothesis, in that inhibition of estrogen biosynthesis (through administration of the aromatase inhibi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A small, controlled study demonstrated that anastrozole in a dose of 1 mg daily during 12 weeks will result in doubling of the mean bioavailable testosterone level in older men [36].”
From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [36]
Citations
Cites
Williams, T., Berelowitz, M., Joffe, S. N., Thorner, M. O., Rivier, J., Vale, W., & Frohman, L. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112203 · Cited by 428
Reduction of Serum Testosterone Levels During Chronic Glucocorticoid Therapy
MacADAMS, M. R., WHITE, R. H., & CHIPPS, B. E. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-5-648 · Cited by 391
ZUMOFF, B., STRAIN, G. W., MILLER, L. K., ROSNER, W., SENIE, R., SERES, D. S., & ROSENFELD, R. S. (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-4-929 · Cited by 349
Self-citationZUMOFF, B., ROSENFELD, R. S., STRAIN, G. W., LEVIN, J., & FUKUSHIMA, D. K. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-51-2-330 · Cited by 187
Self-citationMild hypogonadotropic hypogonadism in obese men
Strain, G. W., Zumoff, B., Kream, J., Strain, J. J., Deucher, R., Rosenfeld, R. S., Levin, J., & Fukushima, D. K. (1982) · Metabolism · doi:10.1016/0026-0495(82)90175-5 · Cited by 175
Self-citationThe Effect of Weight Loss on Reproductive Hormones in Obese Men*
STANIK, S., DORNFELD, L. P., MAXWELL, M. H., VIOSCA, S. P., & KORENMAN, S. G. (1981) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-53-4-828 · Cited by 156
Hormonal Abnormalities in Obesity
ZUMOFF, B. (1987) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1987.tb05939.x · Cited by 110
Self-citationEffect of Massive Weight Loss on Hypothalamic Pituitary-Gonadal Function in Obese Men*
STRAIN, G. W., ZUMOFF, B., MILLER, L. K., ROSNER, W., LEVIT, C., KALIN, M., HERSHCOPF, R. J., & ROSENFELD, R. S. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-66-5-1019 · Cited by 103
Self-citationObese young men have elevated plasma estrogen levels but obese premenopausal women do not
Zumoff, B., Strain, G. W., Kream, J., O'Connor, J., Levin, J., & Fukushima, D. K. (1981) · Metabolism · doi:10.1016/0026-0495(81)90102-5 · Cited by 87
Self-citationEndogenous opioids and hypogonadism in human obesity
Blank, D. M., Clark, R. V., Heymsfield, S. B., Rudman, D. R., & Blank, M. S. (1994) · Brain Research Bulletin · doi:10.1016/0361-9230(94)90142-2 · Cited by 36
Cited by
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
Obesity and androgens: facts and perspectives
Pasquali, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.10.054 · Cited by 469
Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment
Grossmann, M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0118 · Cited by 350
“In the very obese, increased estradiol, because of increased fat-expressed aromatase, decreases gonadotropin levels and thus testosterone, evidenced by the fact that treatment with aromatase inhibitors can normalize testosterone levels and restore spermatogenesis (72).”
BackgroundMichalakis, K., Mintziori, G., Kaprara, A., Tarlatzis, B. C., & Goulis, D. G. (2013) · Metabolism · doi:10.1016/j.metabol.2012.08.012 · Cited by 321
“7 pg/ml), whereas E1 and FSH did not change [239].”
BackgroundAndrogens, insulin resistance and vascular disease in men
Kapoor, D., Malkin, C. J., Channer, K. S., & Jones, T. H. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02299.x · Cited by 317
Metadata
- Authors
- Zumoff, B., Miller, L. K., & Strain, G. W.
- Affiliations
- Mount Sinai Beth Israel (US)
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 52
- Issue
- 9
- Pages
- 1126-1128
- ISSN
- 0026-0495 (ISSN-L)
- OpenAlex
- W2157023352
- Cited by
- 118
- References
- 10
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 7 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 5 · 2017: 9 · 2016: 4 · 2015: 5 · 2014: 12 · 2013: 5 · 2012: 13
- FWCI
- 2.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- hypogonadotropic hypogonadism, obesity, testolactone, aromatase inhibitors, testosterone, luteinizing hormone, follicle-stimulating hormone, estradiol, estrone, hypothalamic-pituitary-gonadal axis, male hypogonadism
- MeSH terms
- Adult, Enzyme Inhibitors, Estradiol, Estrogens, Estrone, Follicle Stimulating Hormone, Humans, Hypogonadism, Luteinizing Hormone, Male, Obesity, Testolactone, Testosterone, Body Mass Index, Aromatase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. https://app.cochat.ai/papers/10.1016/s0026-0495(03)00186-0
- The paper
- Zumoff, B., Miller, L. K., & Strain, G. W. (2003). Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism. https://doi.org/10.1016/s0026-0495(03)00186-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.